Why your joints are telling you something important about your hormones – and the evidence-based approach to protecting them

The Pain That Seems to Come from Nowhere

Many women in their 40s and early 50s describe the same experience: they wake up one morning and their fingers are stiff. Their knees ache when they climb stairs. Their hips feel tight. Their shoulders resist movements that were effortless last year. They assume it is ageing, or that they have been sitting too long at a desk, or that they need to stretch more.

The connection to perimenopause rarely occurs to them. And it rarely occurs to the clinician they see either.

The odds of musculoskeletal pain jump by 63% in perimenopause compared to perimenopause and worsen with progression to postmenopause. More than 50% of women experience arthritis or arthralgia at menopause, contributing to lost mobility, anxiety, and reduced quality of life.

This is not a coincidence, and it is not ageing. It is a well-understood, mechanistically coherent consequence of hormonal change – one that now has an official clinical name and a growing evidence base for treatment.

Part 1: The New Clinical Framework – The Musculoskeletal Syndrome of Menopause

In 2024, researchers formally introduced the term “Musculoskeletal Syndrome of Menopause” (MSM) in a landmark review published in the journal Climacteric – one of the most respected peer-reviewed publications in menopause medicine. The 2024 review in Climacteric introduced the term “musculoskeletal syndrome of menopause” to describe this collective of musculoskeletal signs and symptoms associated with estrogen loss – including arthralgia, loss of muscle mass, loss of bone density, and progression of osteoarthritis. This terminology helps clinicians and patients appreciate the substantial role of decreasing estrogen and anticipate the onset of related symptoms.

The significance of this naming is not merely semantic. Giving a syndrome a name elevates it from a dismissed, fragmented collection of complaints (“your knees hurt, your shoulder is stiff, you’ve got some inflammation”) to a recognized clinical entity with a unifying mechanism, a predictable course, and a structured approach to management. MSM is now a diagnosis that merits attention, investigation, and treatment – not a sigh and a recommendation to take ibuprofen.

The syndrome encompasses:

• Arthralgia – joint pain and stiffness without inflammatory disease
• Sarcopenia – progressive loss of muscle mass and strength
• Osteoporosis – accelerated bone density loss
• Progression of osteoarthritis – particularly in the knees, hips, hands, and spine
• Tendinopathies – including frozen shoulder, gluteal tendinopathy, and plantar fasciitis, which occur at notably higher rates in perimenopausal and postmenopausal women
• Fibromyalgia – which can first emerge or significantly worsen during this hormonal transition

Part 2: How Estrogen Protects Your Joints

Estrogen as Anti-Inflammatory Architect

Estradiol, the most prominent form of estrogen in the body, is a powerful anti-inflammatory hormone. It is known to reduce both joint pain and inflammation. It also helps prevent the breakdown of bone tissue and helps to repair and maintain muscle, which can explain why lean muscle mass decreases as women age.

Estrogen receptors are present in cartilage cells (chondrocytes), synovial tissue (the lining of joint capsules), bone, tendons, ligaments, and the pain-processing regions of the spinal cord. This distribution explains why estrogen loss affects so many aspects of the musculoskeletal system simultaneously – it is not targeting one tissue but withdrawing its regulatory influence from the entire architecture.

Perimenopausal women have fluctuating estrogen levels, which often trigger a range of symptoms as estrogen levels decrease. Changes in perimenopausal estrogen levels are closely related to pain in knee osteoarthritis, which has long been a research area of great interest. Estrogen can affect osteoarthritis pain through the regulation of inflammatory responses, inhibition of cellular senescence and apoptosis, and modulation of neurotransmitters.

The Cartilage Dimension

Cartilage – the smooth, shock-absorbing tissue that cushions the ends of bones within joints – is one of the most estrogen-sensitive structures in the musculoskeletal system.

The dramatic increase in osteoarthritis risk after menopause suggests estrogen deficiency accelerates disease progression. Estrogen deficiency is linked to molecular mechanisms connecting aging and estrogen loss in osteoarthritis development, including cartilage degradation, inflammation, and pain.

Women with higher estradiol levels show measurably less cartilage loss on MRI imaging compared to those with lower levels. Estrogen stimulates collagen synthesis within cartilage and inhibits matrix metalloproteinases – the enzymes that break down cartilage tissue. When estrogen falls, these protective mechanisms fail simultaneously: cartilage production slows and degradation accelerates.

The Inflammatory Cascade

Lower levels of estrogen can lead to reduced cartilage health, as decreased estrogen can affect cartilage integrity, making joints more prone to pain and stiffness. Estrogen helps maintain bone density, and its decline can lead to osteoporosis, contributing to joint pain. Adipose tissue (body fat) can produce inflammatory cytokines that may contribute to joint inflammation and pain.

This inflammatory cascade – driven by falling estrogen, rising pro-inflammatory cytokines (IL-6, TNF-α), and the inflammatory potential of visceral fat that accumulates during menopause – is why MSM feels qualitatively different from the mechanical joint wear of ageing. It has an inflammatory dimension that responds to anti-inflammatory interventions, dietary changes, and – most powerfully – to restoration of estrogen levels.

Why Perimenopause Can Be Worse Than Postmenopause

The pain of perimenopause can be particularly volatile and unpredictable compared to the more stable – if lower – estrogen environment of postmenopause. Wild fluctuations in estrogen levels destabilise the inflammatory regulatory systems that estrogen normally governs. Women describe pain that shifts location, worsens dramatically around hormonal fluctuations, and does not follow the mechanical pattern of conventional arthritis.

This hormonal variability also explains why the same woman may have days of relative comfort followed by days of severe pain – a pattern that confuses both patients and clinicians who are not thinking hormonally.

Part 3: The Most Commonly Affected Joints and Areas

Hands and Fingers

Hand joint pain is frequently the first and most noticeable symptom of MSM – particularly the small joints of the fingers (the proximal and distal interphalangeal joints) and the base of the thumb (the carpometacarpal joint). Morning stiffness that gradually loosens over 30–60 minutes is characteristic. Women describe difficulty opening jars, gripping a pen, or making a fist on waking.

This pattern can be mistaken for inflammatory arthritis (particularly rheumatoid arthritis) – and any hand joint swelling, prolonged morning stiffness, or significant functional limitation should be assessed by a clinician, because distinguishing hormonally-driven arthralgia from early inflammatory disease has important treatment implications.

Knees

The knee is the most extensively studied joint in the context of menopause. The prevalence of knee osteoarthritis increases sharply at midlife – particularly in women – and this sex-specific acceleration is mechanistically linked to estrogen deficiency rather than age alone. Women are significantly more likely to develop knee osteoarthritis after menopause than premenopausal women of the same age, and the pain tends to be bilateral (affecting both knees) rather than the unilateral pattern typical of mechanical osteoarthritis from specific injury.

Hips

Hip pain and stiffness – including the specific entity of gluteal tendinopathy (pain at the outer hip, often worsening with walking, climbing stairs, and lying on the affected side) – is significantly more common in perimenopausal and postmenopausal women. Gluteal tendinopathy is the most common tendon pathology in women and has a particularly strong hormonal association.

Shoulders

Frozen shoulder (adhesive capsulitis) – a condition producing severe shoulder stiffness and pain that typically develops over months and can persist for two to three years – occurs at significantly higher rates in perimenopausal women than in any other demographic. The hormonal connection is increasingly well-documented: estrogen receptors are present in the shoulder joint capsule, and estrogen loss appears to promote the fibrotic process underlying frozen shoulder. Any perimenopausal woman developing progressive shoulder pain and stiffness, particularly with difficulty reaching overhead or behind the back, should seek assessment early – the prognosis is significantly better with early physiotherapy intervention.

Spine and Lower Back

Spinal stiffness, particularly in the lower back and neck, is among the most commonly reported musculoskeletal complaints during perimenopause. The combination of disc dehydration (which estrogen normally partially protects against), reduced paraspinal muscle mass, ligamentous laxity, and inflammatory mediators produces a characteristic pattern of morning stiffness, general achiness, and reduced flexibility that many women experience as a sudden, dramatic change in spinal comfort.

Part 4: The Evidence-Based Treatment Approach

1. Hormone Replacement Therapy: The Most Direct Intervention

For women whose musculoskeletal symptoms are occurring in the context of perimenopause or menopause, addressing the primary cause – hormonal change – is the most mechanistically coherent treatment strategy.

Hormone therapy also reduced the incidence of new musculoskeletal symptoms. A subsequent analysis published in Menopause confirmed that estrogen-alone use in postmenopausal women results in a modest but sustained reduction in the frequency of joint pain.

A 2024 meta-analysis of 18 studies involving 12,400 women showed that HRT formulations reduced joint pain scores by an average of 3.2 points on a 10-point scale. The Women’s Health Initiative follow-up studies – tracking 27,000 participants – found that women receiving estrogen therapy had 23% fewer arthritis diagnoses and required 31% fewer joint replacement surgeries over 15 years of follow-up.

The anti-inflammatory effects of estrogen begin within 4–8 weeks of treatment initiation, with peak benefits occurring after 3–6 months. For women already on HRT for vasomotor, mood, or bone health reasons, joint symptom improvement is a documented, though often unreported, secondary benefit.

2. Exercise: The Most Important Non-Pharmacological Intervention

Exercise for joint pain during menopause is not a generic recommendation – it requires understanding which types of exercise produce benefit through different mechanisms.

Resistance training is the highest-priority modality. It preserves and rebuilds the muscle mass that protects joints from mechanical loading – every kilogram of muscle around a knee reduces joint loading by approximately four kilograms. It stimulates the synthesis of cartilage matrix proteins, reduces systemic inflammation through myokine release, and maintains bone density that contributes to joint structural integrity. Two to three sessions per week, targeting all major muscle groups, with progressive loading, is the evidence-based frequency.

Low-impact aerobic exercise – swimming, cycling, walking, and elliptical training – maintains cardiovascular fitness and joint mobility without the high mechanical loading that inflamed joints cannot tolerate in the acute phase. Walking in particular loads the joints in the functional range of motion that preserves cartilage health over time.

Targeted physiotherapy for specific joint problems – frozen shoulder, gluteal tendinopathy, knee osteoarthritis – is significantly more effective than generic exercise programs. A physiotherapist with expertise in menopause-related musculoskeletal conditions can design a program specific to the joint involved, the degree of inflammation, and the woman’s functional goals.

Yoga, Pilates, and tai chi improve joint range of motion, muscle strength around joints, balance (reducing fall risk), and pain perception through mind-body mechanisms including HPA axis regulation and central pain processing. Evidence for their specific benefit in menopausal joint pain is growing.

What to avoid: high-impact activities (running, jumping) during acute joint inflammation phases. The error many women make is stopping all exercise when joint pain begins – which accelerates muscle loss, worsens inflammation, and reduces joint stability. The correct response is to modify rather than cease.

3. Anti-Inflammatory Nutrition: The Dietary Architecture That Matters

The anti-inflammatory diet has the strongest evidence base for musculoskeletal health in this population, and it aligns precisely with the pattern of highest overall evidence for menopause health generally – the Mediterranean diet.

Omega-3 fatty acids are the most evidence-supported specific nutritional intervention for joint pain. EPA and DHA from oily fish (salmon, mackerel, sardines, herring) and algae-based supplements reduce the production of prostaglandins and cytokines that drive joint inflammation. Clinical trials in osteoarthritis demonstrate measurable reduction in pain scores and morning stiffness with omega-3 supplementation at 2–3g EPA+DHA daily. This is not a subtle effect – it approaches the analgesic benefit of low-dose NSAIDs without the gastrointestinal or renal risks.

Collagen peptides – 10–15g daily of specific collagen hydrolysates – have accumulated a reasonable evidence base for reducing joint pain in athletes and populations with osteoarthritis. The proposed mechanism involves delivery of proline-rich peptides to joint cartilage, stimulating chondrocyte activity. The evidence is not yet definitive but is increasingly positive in well-designed trials.

Vitamin D – essential for calcium absorption and bone health, but also directly involved in muscle function and inflammatory regulation. Deficiency (present in 40–70% of postmenopausal women in temperate climates) is associated with musculoskeletal pain and weakness. Testing and correcting to above 50 nmol/L is a foundational step.

Magnesium – involved in over 300 enzymatic processes, including muscle contraction, ATP production, and inflammatory regulation. Frequently deficient in perimenopausal women. Food sources: dark leafy greens, pumpkin seeds, almonds, dark chocolate. Supplemental magnesium glycinate (300–400 mg daily) is well-tolerated.

Curcumin (from turmeric) – has demonstrated anti-inflammatory effects comparable to ibuprofen in small clinical trials for knee osteoarthritis pain, without gastrointestinal effects. Bioavailability is low from dietary turmeric alone; supplemental forms with piperine or phospholipid complexes achieve clinically meaningful serum levels. 500–1,000 mg daily of a high-bioavailability formulation is the dose used in most positive trials.

Vitamin K2 (menaquinone MK-7) – directs calcium into bone and teeth rather than soft tissues and blood vessels. Emerging evidence supports its role in cartilage health and inflammation reduction. Found in natto, hard cheeses, and egg yolks; supplemental MK-7 at 100–200 mcg daily is increasingly recommended alongside vitamin D.

Glucosamine and chondroitin – long-used supplements for osteoarthritis. Evidence is mixed: some large trials show no benefit over placebo, while others show meaningful benefit for specific subgroups (moderate to severe knee osteoarthritis, in particular). They are well-tolerated and carry no significant safety concerns, making a trial in women with established osteoarthritis symptoms reasonable.

4. Weight Management: The Mechanical and Inflammatory Dimension

Excess weight puts additional stress on weight-bearing joints. Extra weight can accelerate the wear and tear on joints, exacerbating pain and stiffness. Adipose tissue can produce inflammatory cytokines that may contribute to joint inflammation and pain.

Every kilogram of excess body weight translates to approximately 3–4 kilograms of additional force on the knee joint during walking. This mechanical reality is compounded during menopause by the fact that visceral adipose tissue is itself an inflammatory organ – producing IL-6, TNF-α, and other cytokines that directly worsen joint inflammation. Weight management during this transition is therefore simultaneously a mechanical and anti-inflammatory intervention.

5. Pain Management and Targeted Medications

NSAIDs (ibuprofen, naproxen, diclofenac) – effective short-term for acute inflammatory flares. Regular long-term use carries gastrointestinal, renal, and cardiovascular risks that increase with age. Should be used at the lowest effective dose for the shortest necessary duration, ideally with food.

Topical NSAIDs (diclofenac gel) – provide local anti-inflammatory effect with significantly lower systemic absorption than oral formulations. Evidence-supported for knee and hand osteoarthritis pain, with an excellent safety profile for regular use.

Duloxetine – an SNRI antidepressant with specific FDA approval for chronic musculoskeletal pain, including osteoarthritis. Its mechanism involves central pain modulation rather than peripheral anti-inflammation. Particularly relevant for women whose musculoskeletal pain has a significant central sensitisation component (pain that has become disproportionate to the structural finding, or that is widespread and associated with fatigue and cognitive symptoms).

Intra-articular injections – corticosteroid injections provide meaningful short-term relief for acute joint flares; hyaluronic acid injections have more modest but longer-lasting effects in knee osteoarthritis. Platelet-rich plasma (PRP) injections have emerging evidence for tendinopathies including gluteal tendinopathy and rotator cuff conditions.

Part 5: When to Seek Specialist Assessment

Not all joint pain during perimenopause is MSM. Several conditions require specific diagnosis and are clinically important to distinguish:

See a clinician promptly for:

• Joint swelling, redness, or warmth – signs of active joint inflammation that may indicate rheumatoid arthritis, gout, or pseudogout, all of which require specific treatment
• Morning stiffness lasting more than 45–60 minutes – more characteristic of inflammatory arthritis than MSM
• Pain that is monoarticular (affecting only one specific joint) without a clear mechanical explanation
• Symmetrical small joint involvement of the hands, wrists, and feet – the distribution pattern of rheumatoid arthritis
• Any joint pain accompanied by systemic symptoms – fever, weight loss, fatigue out of proportion to musculoskeletal symptoms
• Rapid progression of joint pain or functional limitation over weeks rather than months

Blood tests useful in this context: CRP and ESR (markers of systemic inflammation), rheumatoid factor and anti-CCP antibodies (for rheumatoid arthritis), uric acid (for gout), ANA (for autoimmune conditions), and thyroid function – hypothyroidism commonly produces a musculoskeletal picture closely mimicking MSM.

Part 6: The Practical Daily Framework

Morning: Before getting out of bed, spend 3–5 minutes gently moving stiff joints – ankle circles, finger flexion and extension, knee bends while lying down. Warmth (a brief warm shower or bath) reduces morning stiffness significantly by promoting synovial fluid circulation.

Nutrition: At least two portions of oily fish weekly, or daily omega-3 supplementation at 2–3g EPA+DHA. Vitamin D tested and supplemented to above 50 nmol/L. Magnesium glycinate 300 mg before bed. An anti-inflammatory dietary pattern (Mediterranean) as the overall framework.

Movement: Daily low-impact activity – a 20–30 minute walk at minimum. Resistance training two to three times weekly. Avoid extended periods of sitting or standing in the same position, which reduces synovial fluid circulation.

Sleep: Adequate, restorative sleep is essential for pain processing and inflammation regulation. Sleep deprivation amplifies pain perception through central sensitization mechanisms – and the night sweats of perimenopause that fragment sleep directly worsen musculoskeletal pain the following day.

Medical review: If joint symptoms are significantly affecting daily life, discuss with your GP or a rheumatologist. Request the blood tests above. Discuss MHT as a potential component of management. Ask for physiotherapy referral for specific joint problems. Do not accept “it’s your age” without appropriate investigation.

The Honest Conclusion

Joint pain during perimenopause and menopause is not simply an inconvenience of getting older. It is the Musculoskeletal Syndrome of Menopause – a recognized, hormone-driven clinical entity affecting the majority of women in this transition, with measurable impact on quality of life, function, and long-term joint health.

The good news is that the mechanism is understood, the syndrome is named, and the treatment options – from HRT to targeted exercise, from anti-inflammatory nutrition to specific physiotherapy – are both evidence-based and largely accessible. The key is to stop accepting the pain as inevitable and to start treating it as the treatable symptom it is.

Your joints are telling you something important about your hormones. It is time to listen.

For more useful articles and expert guidance, explore the Womeno app – your personal digital companion through the hormonal transition. Download the app HERE

Sources

1. Wright VJ, Schwartzman JD, Itinoche R, Wittstein J. The musculoskeletal syndrome of menopause. Climacteric. 2024;27(5):466–472. doi:10.1080/13697137.2024.2380363
2. Zhao H, Yu F, Wu W. The Mechanism by Which Estrogen Level Affects Knee Osteoarthritis Pain in Perimenopause and Non-Pharmacological Measures. International Journal of Molecular Sciences. 2025;26(6):2391. PMC11942494. doi:10.3390/ijms26062391
3. Yue H et al. The intersection of aging and estrogen in osteoarthritis. npj Women’s Health. 2025;3:15. doi:10.1038/s44294-025-00063-1
4. Onuora S. Oestrogens implicated in progression to arthritis. Nature Reviews Rheumatology. 2025. doi:10.1038/s41584-025-01242-9
5. American Academy of Orthopaedic Surgeons (AAOS) / OrthoInfo. Musculoskeletal Syndrome of Menopause. orthoinfo.aaos.org. Updated February 2026. (Citing: WHI follow-up; SWAN study data)
6. Bonza Health. Menopause Joint Pain and Arthritis Relief: Understanding the Musculoskeletal Syndrome. bonzahealth.com. December 2025.
7. Rheumatology Advisor. Managing Musculoskeletal Health in Menopause Requires Multidisciplinary, Holistic Approach. rheumatologyadvisor.com. April 2025. (Citing: Wright et al. 2024 Climacteric; Manson JE et al. JAMA 2024)
8. Grimaldi A. Menopause and Musculoskeletal Health: Why it matters. dralisongrimaldi.com. August 2025.
9. Whole Health Rheumatology / Pinkston O MD. Musculoskeletal Syndrome of Menopause. wholehealthrheum.com. 2025.
10. Hinge Health. Musculoskeletal Syndrome of Menopause: What to Know. hingehealth.com. January 2025. (Citing: Wright et al. 2024)
11. Dr. Mary Claire Haver. Musculoskeletal Syndrome of Menopause: What You Need to Know. thepauselife.com. (Citing: Wright et al. 2024; Hang X et al. 2021; Martin-Millan M et al. 2023)
12. Loyola Medicine. Menopause-Related Musculoskeletal Pain. loyolamedicine.org. January 2026.
13. Paloma Health. Joint Pain in Perimenopause and Menopause. palomahealth.com. September 2025.
14. Formblends. HRT for Joint Pain: How Hormones Affect Inflammation. formblends.com. April 2026.
15. Manson JE, Crandall CJ, Rossouw JE et al. The Women’s Health Initiative randomized trials and clinical practice: a review. JAMA. 2024;331(20):1748–1760. doi:10.1001/jama.2024.6542
16. Lu CB et al. Musculoskeletal pain during the menopausal transition: A systematic review and meta-analysis. Neural Plasticity. 2020;2020:8842110.